Eventide Asset Management LLC Invests $12.97 Million in CG Oncology, Inc. $CGON

Posted by Brian Himes on Jun 15th, 2026

Eventide Asset Management LLC acquired a new position in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 312,445 shares of the company’s stock, valued at approximately $12,972,000.

Several other institutional investors also recently modified their holdings of the company. Whittier Trust Co. of Nevada Inc. bought a new position in CG Oncology in the 4th quarter worth approximately $27,000. Comerica Bank raised its position in CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after purchasing an additional 515 shares during the last quarter. Picton Mahoney Asset Management bought a new position in CG Oncology in the 4th quarter worth approximately $118,000. Mirae Asset Global Investments Co. Ltd. raised its position in CG Oncology by 33.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock worth $163,000 after purchasing an additional 972 shares during the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of CG Oncology during the 3rd quarter valued at $221,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

Insider Buying and Selling at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $54.50, for a total transaction of $54,500.00. Following the completion of the transaction, the director directly owned 1,000 shares in the company, valued at $54,500. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James Mulay sold 15,600 shares of CG Oncology stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the transaction, the director owned 15,600 shares of the company’s stock, valued at $1,138,956. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 4.80% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Wedbush upped their target price on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a research note on Monday, May 18th. Truist Financial reaffirmed a “buy” rating and issued a $82.00 target price (up from $77.00) on shares of CG Oncology in a report on Thursday, May 14th. Finally, Royal Bank Of Canada increased their price target on shares of CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, CG Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $81.73.

Read Our Latest Stock Analysis on CG Oncology

CG Oncology Price Performance

Shares of CG Oncology stock opened at $59.56 on Monday. The firm has a market capitalization of $5.25 billion, a P/E ratio of -25.56 and a beta of 0.31. The company’s 50 day moving average price is $65.05 and its two-hundred day moving average price is $56.63. CG Oncology, Inc. has a fifty-two week low of $23.65 and a fifty-two week high of $75.50.

CG Oncology (NASDAQ:CGON – Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.45 million. On average, analysts expect that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

About CG Oncology

(Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.